SCHEMBL2803040

SCHEMBL2803040

COCCN1CCN(c2cccc(F)c2N)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 1/20 0.47
ADORA2B P29275 1/20 0.45
HTR4 Q13639 1/20 0.45
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 2/20 0.44
TSHR P16473 2/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
DRD2 P14416 2/20 0.43
HTR2A P28223 1/20 0.43
HRH1 P35367 1/20 0.43
LMNA P02545 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A3 Q01959 2/20 0.42
MAP4K4 O95819 1/20 0.42
MAPT P10636 1/20 0.42
NLRP1 Q9C000 1/20 0.42
SLC6A4 P31645 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2783063 0.86 DRD2 (0.54) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2783046 0.84 SMN1; SMN2 (0.48) SMN1; SMN2MAPK1ALDH1A1KDM4ETSHR
SCHEMBL2782106 0.84 DRD2 (0.56) ALDH1A1KDM4ETSHRPOLBDRD2
SCHEMBL27684034 0.84 SMN1; SMN2 (0.51) SMN1; SMN2MAPK1ADORA2BHTR4ALDH1A1
SCHEMBL2782579 0.83 DRD2 (0.53) SMN1; SMN2MAPK1ADORA2BHTR4ALDH1A1
SCHEMBL2783739 0.83 DRD2 (0.52) ADORA2BHTR4KDM4EDRD2HTR2A
SCHEMBL2781296 0.83 ALDH1A1 (0.49) SMN1; SMN2MAPK1ADORA2BHTR4ALDH1A1
SCHEMBL21301972 0.83 ADORA2B (0.51) ADORA2BHTR4ALDH1A1KDM4ETSHR
SCHEMBL2782122 0.83 GRM2 (0.41) L3MBTL1DRD2HTR2AMAP4K4
SCHEMBL2783095 0.81 SMN1; SMN2 (0.45) SMN1; SMN2MAPK1ADORA2BHTR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2010-10-07 US claimed
EP-2204363-A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-07-07 EP claimed
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2007-06-28 US claimed
US-8314126-B2 Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2012-11-20 US disclosed
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2010-10-07 US disclosed
US-7763639-B2 Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2010-07-27 US disclosed
EP-2204363-A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-07-07 EP disclosed
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, DRD4, DRD1 SMN1; SMN2 1353/4885MAPK1 639/4885ADORA2B 327/4885
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, DRD4, DRD1 SMN1; SMN2 1180/4885MAPK1 597/4885ADORA2B 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.